We’ve all been closely following Geron and its work on ES cells. This morning there was a fantastic session here at the ASGCT meeting in Seattle on Clinical Trials on Stem Cells. Talk by Geron One of the speakers was Geron VP, Jane Lebkoswki, PhD: Development of Human Embryonic Stem Cell-Based Therapies for Treatment of […]
Stem Cell Clinical Trials Part I: Geron VP Lebkoswki speaking today in Seattle Read More »
There were three talks today on iPS cells here at the American Society for Gene and Cell Therapy meeting or ASGCT meeting in Seattle. Dr. James Ellis made the interesting case that it may be preferable to make iPS cells using genetic methods (while everyone else seems to be saying that non-genetic methods will be better).
News on iPS cells from some top scientists at ASGCT meeting today Read More »
Why invest in stem cells? Ideas are the foundation of stem cell research, but funding makes those ideas a reality. We talk a lot about governmental funding of stem cell research through CIRM and NIH. The funding from these agencies is essential and will undoubtedly lead to new treatments and cures, possibly for millions of
Why invest in stem cells? Progress, Patients, and Patents Read More »
There are a lot of myths in the stem cell field, some even embraced by some stem cell scientists such as the notion that teratoma are always benign. But when we start talking about translating stem cell technology into the clinic, to the bedside, it is especially important to cast aside our myths, no
Myth of Perfect Stem Cell: meaning for ACT, Geron and field Read More »
Who’s who in the field of iPS cells? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
What are iPS cells? We talk about iPS cells all the time. We are very excited about them. Heck, the web address for this blog is ipscell.com. But what are iPSCs, really? iPS cells definition A simple definition of iPSCs is the following: Embryonic stem cell-like cells that are made from non-stem cells in a
An insider’s guide: what are iPS cells? Read More »
Now and then we will revisit some of our most popular posts and/or posts with the most comments. One of the best: The Monster Tumor: What is a teratoma really? You can go to the link above to read the original post and comments but I’ve pasted the post itself below. In stem cell research
Greatest hits: What is a teratoma? Read More »
For many of us in the biomedical research field, we have always wanted to be a professor and run our own research lab even if it meant the gauntlet of the dreaded academic job search. For some it is fair to say that that goal is really a passion, a dream. However, to achieve
Advice for the academic job search Read More »
The Oklahoma State Legislature is reportedly poised to potentially pass an outright ban of ES cell research. While in the past similar legislation was vetoed by previous Oklahoma Governor, Democrat Brad Henry, current Republican Governor Mary Fallin is likely to sign the legislation. The Oklahoman newspaper website today contains a factually incorrect, inflammatory piece by
Oklahoma leaders: ES cell research is not OK Read More »
It’s been more than 4 years since Shinya Yamanaka published the remarkable finding that his lab could transform or “reprogram” regular cells called fibroblasts into a very unique state that was quite similar to that of embryonic stem cells (ESC). Yamanaka called these new cells “iPS cells” for induced pluripotent stem cells. iPS cells Since
The Inside Scoop on iPS cells early in 2011 Read More »